Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20344162 | 0.82 | PDE10A (0.33) | HDAC1PDE10A | |
| SCHEMBL10143645 | 0.78 | PDE10A (0.38) | HDAC1CCR1PDE10A | |
| SCHEMBL26125177 | 0.78 | CCR1 (0.32) | CCR1 | |
| SCHEMBL18789807 | 0.77 | HDAC1 (0.35) | HDAC1PDE10A | |
| SCHEMBL17285611 | 0.73 | ALDH1A1 (0.54) | HDAC1PDE10A | |
| SCHEMBL20162086 | 0.72 | HDAC1 (0.35) | HDAC1PDE10A | |
| SCHEMBL17626629 | 0.72 | SUV39H2 (0.44) | HDAC1PDE10A | |
| SCHEMBL5769043 | 0.70 | ALDH1A1 (0.38) | CCR1 | |
| SCHEMBL12341046 | 0.69 | PDE10A (0.33) | HDAC1PDE10A | |
| SCHEMBL12343964 | 0.69 | PDE8B (0.35) | HDAC1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145930-B1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | Celon Pharma Sa (PL) | 2018-07-04 | — | — | EP | disclosed |
| US-20170114064-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | CELON PHARMA S.A. (PL) | 2017-04-27 | — | — | US | disclosed |
| US-20170114064-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | CELON PHARMA S.A. (PL) | 2017-04-27 | — | — | US | disclosed |
| WO-2015177688-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | CELON PHARMA S.A. (PL) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114064-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | PDE3B, PDE3A, PDE5A | HDAC1 156/4885CCR1 3887/4885PDE10A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.